Scroccaro (Veneto): “Approval of orphan drugs in certain times”

“It is imperative to continue on the path that has been undertaken, that is to guarantee the approval of orphan drugs in certain times. The speed with which the negotiation of a drug, orphan or non-orphan, is closed, is strongly linked to will and acceptance. by the proposing company of the price proposed by the Price and Reimbursement Committee (Cpr). The process involves an evaluation by the Technical-Scientific Committee (Cts), especially on the clinical value of the drug and its superiority over the alternatives , when these alternatives are available. On the basis of these main considerations, the CPR proposes a price to the company. It is true that the company presents itself with its own dossier, with its own price, but the CPR makes its proposal. If a mediation is found between the price requested by the company, which is always higher than the one proposed by the Price and Refund Committee, the negotiation is concluded quickly. nto on both sides, the times are much longer “. This was explained by Giovanna Scroccaro, Director of Pharmaceutical, Prosthetics and Medical Devices of the Veneto Region, who spoke this morning at the round table ‘Pnrr & Governance on the territory’, on the occasion of the presentation of the 5th Ossfor Report. “I invite pharmaceutical companies to carefully evaluate the opinion of the CTS, because from a careful reading they can also already understand what the price request that is made may be – he added – To patient associations, who rightly solicit the drug as soon as possible possible time, I say to become promoters to pharmaceutical companies to request that the price be fair. The fair price, in fact, guarantees greater access by many citizens and also guarantees general sustainability which, in turn, will determine quick access for subsequent drugs “.